Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients
نویسندگان
چکیده
منابع مشابه
Monoclonal antibody pharmacokinetics and pharmacodynamics.
More than 20 monoclonal antibodies have been approved as therapeutic drugs by the US Food and Drug Administration, and it is quite likely that the number of approved antibodies will double in the next 7-10 years. Antibody drugs show several desirable characteristics, including good solubility and stability, long persistence in the body, high selectivity and specificity, and low risk for bioconv...
متن کاملPopulation Pharmacokinetics of Necitumumab in Cancer Patients
Necitumumab is a second-generation, recombinant, human immunoglobulin G1, epidermal growth factor (EGFR) receptor antibody that specifically blocks the ligand binding site of EGFR. Necitumumab potentially acts by blocking ligand epidermal growth factor (EGF) binding-mediated activation of the EGFR signaling pathway, inhibiting tumor growth, angiogenesis, and anti-apoptotic mechanisms. Necitumum...
متن کاملApplication of Behavioral Activation Ttreatment for Depression in Cancer Patients
Objectives: Major depression and anxiety disorders are common psychiatric disorders among cancer patients and are associated with psychosocial impairment and decreased quality of life. Depressed and anxious cancer patients also experience a more rapid progression of cancer symptoms, increased mortality, more metastasis and pain, and increased medical utilization. Although some research has expl...
متن کاملPopulation Pharmacokinetics of Sifalimumab, an Investigational Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus
BACKGROUND AND OBJECTIVES Sifalimumab is a fully human immunoglobulin G1κ monoclonal antibody that binds to and neutralizes a majority of the subtypes of human interferon-α. Sifalimumab is being evaluated as a treatment for systemic lupus erythematosus (SLE). The primary objectives of this analysis were (a) to develop a population pharmacokinetic model for sifalimumab in SLE; (b) to identify an...
متن کاملPopulation pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children.
Although it has been on the market for over a decade, confusion remains regarding the pharmacokinetics (PK) and optimal dosing of palivizumab, a humanized IgG1κ monoclonal antibody indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease. The objectives of this analysis were to character...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Clinical Pharmacology
سال: 2001
ISSN: 0306-5251
DOI: 10.1111/j.1365-2125.2001.01335.x